718 related articles for article (PubMed ID: 29144447)
1. BCAT1 restricts αKG levels in AML stem cells leading to IDHmut-like DNA hypermethylation.
Raffel S; Falcone M; Kneisel N; Hansson J; Wang W; Lutz C; Bullinger L; Poschet G; Nonnenmacher Y; Barnert A; Bahr C; Zeisberger P; Przybylla A; Sohn M; Tönjes M; Erez A; Adler L; Jensen P; Scholl C; Fröhling S; Cocciardi S; Wuchter P; Thiede C; Flörcken A; Westermann J; Ehninger G; Lichter P; Hiller K; Hell R; Herrmann C; Ho AD; Krijgsveld J; Radlwimmer B; Trumpp A
Nature; 2017 Nov; 551(7680):384-388. PubMed ID: 29144447
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis of IDH-mutant cancers identifies EBF1 as an interaction partner for TET2.
Guilhamon P; Eskandarpour M; Halai D; Wilson GA; Feber A; Teschendorff AE; Gomez V; Hergovich A; Tirabosco R; Fernanda Amary M; Baumhoer D; Jundt G; Ross MT; Flanagan AM; Beck S
Nat Commun; 2013; 4():2166. PubMed ID: 23863747
[TBL] [Abstract][Full Text] [Related]
3. High expression of BCAT1 sensitizes AML cells to PARP inhibitor by suppressing DNA damage response.
Pan J; Wang Y; Huang S; Mao S; Ling Q; Li C; Li F; Yu M; Huang X; Huang J; Lv Y; Li X; Ye W; Wang H; Wang J; Jin J
J Mol Med (Berl); 2024 Mar; 102(3):415-433. PubMed ID: 38340163
[TBL] [Abstract][Full Text] [Related]
4. Cancer progression by reprogrammed BCAA metabolism in myeloid leukaemia.
Hattori A; Tsunoda M; Konuma T; Kobayashi M; Nagy T; Glushka J; Tayyari F; McSkimming D; Kannan N; Tojo A; Edison AS; Ito T
Nature; 2017 May; 545(7655):500-504. PubMed ID: 28514443
[TBL] [Abstract][Full Text] [Related]
5. TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group.
Gaidzik VI; Paschka P; Späth D; Habdank M; Köhne CH; Germing U; von Lilienfeld-Toal M; Held G; Horst HA; Haase D; Bentz M; Götze K; Döhner H; Schlenk RF; Bullinger L; Döhner K
J Clin Oncol; 2012 Apr; 30(12):1350-7. PubMed ID: 22430270
[TBL] [Abstract][Full Text] [Related]
6. BCAT1 promotes cell proliferation through amino acid catabolism in gliomas carrying wild-type IDH1.
Tönjes M; Barbus S; Park YJ; Wang W; Schlotter M; Lindroth AM; Pleier SV; Bai AHC; Karra D; Piro RM; Felsberg J; Addington A; Lemke D; Weibrecht I; Hovestadt V; Rolli CG; Campos B; Turcan S; Sturm D; Witt H; Chan TA; Herold-Mende C; Kemkemer R; König R; Schmidt K; Hull WE; Pfister SM; Jugold M; Hutson SM; Plass C; Okun JG; Reifenberger G; Lichter P; Radlwimmer B
Nat Med; 2013 Jul; 19(7):901-908. PubMed ID: 23793099
[TBL] [Abstract][Full Text] [Related]
7. Focal disruption of DNA methylation dynamics at enhancers in IDH-mutant AML cells.
Wilson ER; Helton NM; Heath SE; Fulton RS; Payton JE; Welch JS; Walter MJ; Westervelt P; DiPersio JF; Link DC; Miller CA; Ley TJ; Spencer DH
Leukemia; 2022 Apr; 36(4):935-945. PubMed ID: 34873300
[TBL] [Abstract][Full Text] [Related]
8. [Research Progress of Isocitrate Dehydrogenase Mutation-Positive Acute Myeloid Leukemia --Review].
Ye F; Ma J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Apr; 32(2):630-633. PubMed ID: 38660877
[TBL] [Abstract][Full Text] [Related]
9. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation.
Figueroa ME; Abdel-Wahab O; Lu C; Ward PS; Patel J; Shih A; Li Y; Bhagwat N; Vasanthakumar A; Fernandez HF; Tallman MS; Sun Z; Wolniak K; Peeters JK; Liu W; Choe SE; Fantin VR; Paietta E; Löwenberg B; Licht JD; Godley LA; Delwel R; Valk PJ; Thompson CB; Levine RL; Melnick A
Cancer Cell; 2010 Dec; 18(6):553-67. PubMed ID: 21130701
[TBL] [Abstract][Full Text] [Related]
10. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of α-ketoglutarate-dependent dioxygenases.
Xu W; Yang H; Liu Y; Yang Y; Wang P; Kim SH; Ito S; Yang C; Wang P; Xiao MT; Liu LX; Jiang WQ; Liu J; Zhang JY; Wang B; Frye S; Zhang Y; Xu YH; Lei QY; Guan KL; Zhao SM; Xiong Y
Cancer Cell; 2011 Jan; 19(1):17-30. PubMed ID: 21251613
[TBL] [Abstract][Full Text] [Related]
11. METTL16 drives leukemogenesis and leukemia stem cell self-renewal by reprogramming BCAA metabolism.
Han L; Dong L; Leung K; Zhao Z; Li Y; Gao L; Chen Z; Xue J; Qing Y; Li W; Pokharel SP; Gao M; Chen M; Shen C; Tan B; Small A; Wang K; Zhang Z; Qin X; Yang L; Wunderlich M; Zhang B; Mulloy JC; Marcucci G; Chen CW; Wei M; Su R; Chen J; Deng X
Cell Stem Cell; 2023 Jan; 30(1):52-68.e13. PubMed ID: 36608679
[TBL] [Abstract][Full Text] [Related]
12. Branched-chain amino acid transaminase 1 (BCAT1) promotes the growth of breast cancer cells through improving mTOR-mediated mitochondrial biogenesis and function.
Zhang L; Han J
Biochem Biophys Res Commun; 2017 Apr; 486(2):224-231. PubMed ID: 28235484
[TBL] [Abstract][Full Text] [Related]
13. IDH mutations in cancer and progress toward development of targeted therapeutics.
Dang L; Yen K; Attar EC
Ann Oncol; 2016 Apr; 27(4):599-608. PubMed ID: 27005468
[TBL] [Abstract][Full Text] [Related]
14. Genetic Polymorphism Study of IDH 1/2 and TET2 Genes in Acute Myeloid leukemia Patients.
Atef M; Shafik NF; H A Hassan N; Allam RM; El-Meligui YM; Abdelaziz H
Asian Pac J Cancer Prev; 2023 Sep; 24(9):3169-3182. PubMed ID: 37774069
[TBL] [Abstract][Full Text] [Related]
15. Enasidenib and ivosidenib in AML.
Martelli MP; Martino G; Cardinali V; Falini B; Martinelli G; Cerchione C
Minerva Med; 2020 Oct; 111(5):411-426. PubMed ID: 32955829
[TBL] [Abstract][Full Text] [Related]
16. Human acute leukemia uses branched-chain amino acid catabolism to maintain stemness through regulating PRC2 function.
Kikushige Y; Miyamoto T; Kochi Y; Semba Y; Ohishi M; Irifune H; Hatakeyama K; Kunisaki Y; Sugio T; Sakoda T; Miyawaki K; Kato K; Soga T; Akashi K
Blood Adv; 2023 Jul; 7(14):3592-3603. PubMed ID: 36044390
[TBL] [Abstract][Full Text] [Related]
17. The role of mutant IDH1 and IDH2 inhibitors in the treatment of acute myeloid leukemia.
Nassereddine S; Lap CJ; Haroun F; Tabbara I
Ann Hematol; 2017 Dec; 96(12):1983-1991. PubMed ID: 29090344
[TBL] [Abstract][Full Text] [Related]
18. Regulation of branched-chain amino acid metabolism by hypoxia-inducible factor in glioblastoma.
Zhang B; Chen Y; Shi X; Zhou M; Bao L; Hatanpaa KJ; Patel T; DeBerardinis RJ; Wang Y; Luo W
Cell Mol Life Sci; 2021 Jan; 78(1):195-206. PubMed ID: 32088728
[TBL] [Abstract][Full Text] [Related]
19. The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches.
Gruber E; Kats LM
Biochem Soc Trans; 2023 Aug; 51(4):1675-1686. PubMed ID: 37526143
[TBL] [Abstract][Full Text] [Related]
20. Distinct and opposite effects of leukemogenic
Fortin J; Chiang MF; Meydan C; Foox J; Ramachandran P; Leca J; Lemonnier F; Li WY; Gams MS; Sakamoto T; Chu M; Tobin C; Laugesen E; Robinson TM; You-Ten A; Butler DJ; Berger T; Minden MD; Levine RL; Guidos CJ; Melnick AM; Mason CE; Mak TW
Proc Natl Acad Sci U S A; 2023 Jan; 120(4):e2208176120. PubMed ID: 36652477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
